文献速递慢性肾脏病

可溶性ST2与半乳糖凝集素3与CKD进展的关系

Soluble ST2 and Galectin-3 and Progression of CKD.
PubMed 文献 · Kidney Int Rep · 2018-09-21

该研究 pooled 分析了 C-PROBE 和 SKS 两个 CKD 队列共 841 名参与者,基线 eGFR 为 51 ± 27 ml/min per 1.73 m2,中位 UACR 为 141(IQR 15-736)mg/g。在校正人口学、肾功能和合并症后,sST2 每翻倍与进展至 eGFR <15 或 ESRD 无显著关联(aHR 1.02,95%CI 0.76-1.38),而 galectin-3 每翻倍与进展风险增加 38% 显著相关(aHR 1.35,95%CI 1.01-1.80)。结论提示较高的 galectin-3 可能与 CKD 进展相关。

要点

  • sST2 每翻倍与 CKD 进展至 eGFR<15 或 ESRD 无显著关联。
  • galectin-3 每翻倍与 CKD 进展风险增加 38% 独立相关。
  • galectin-3 或反映心脏炎症/纤维化参与 CKD 进展的新机制。

核心结论

  • 较高的心脏生物标志物 galectin-3 可能与 CKD 进展相关,提示潜在新机制。

研究设计与样本

  • pooled 分析 C-PROBE 和 SKS 两个纵向 CKD 队列,共 841 名参与者。
  • 基线测量循环 sST2 和 galectin-3 浓度,主要结局为进展至 eGFR <15 ml/min per 1.73 m2 或 ESRD。
  • 采用竞争风险 Cox 回归模型,校正人口学、肾功能和合并症。

主要发现

  • 基线 eGFR 为 51 ± 27 ml/min per 1.73 m2,中位 UACR 为 141(IQR 15-736)mg/g。
  • sST2 和 galectin-3 较高者更可能年龄较大、合并心衰和糖尿病、eGFR 较低。
  • 校正后 sST2 每翻倍与结局无显著关联(aHR 1.02,95%CI 0.76-1.38)。
  • 校正后 galectin-3 每翻倍与结局风险增加 38% 显著相关(aHR 1.35,95%CI 1.01-1.80)。

临床怎么用

  • galectin-3 或可作为 CKD 进展风险分层的候选生物标志物,但需进一步验证。
  • sST2 在此队列中未显示与 CKD 进展的独立关联,不建议单独用于风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiac biomarkers soluble ST2 (sST2) and galectin-3 may reflect cardiac inflammation and fibrosis. It is plausible that these mechanisms may also contribute to the progression of kidney disease. We examined associations of sST2 and galectin-3 with kidney function decline in participants with chronic kidney disease (CKD). METHODS: This was a pooled analysis of 2 longitudinal cohorts of participants with CKD: the Clinical Phenotyping and Resource Biobank (C-PROBE) study and the Seattle Kidney Study (SKS). We measured circulating concentrations of sST2 and galectin-3 at baseline. Our primary outcome was progression to estimated glomerular filtration rate (eGFR) <15 ml/min per 1.73 m2 or end-stage renal disease (ESRD). We used competing risk Cox regression models to study the association of sST2 and galectin-3 with CKD progression, adjusting for demographics, kidney function, and comorbidity. RESULTS: Among the 841 participants in the pooled cohort, baseline eGFR was 51 ± 27 ml/min per 1.73 m2 and median urine albumin-to-creatinine ratio (UACR) was 141 (interquartile range = 15-736) mg/g. Participants with higher sST2 and galectin-3 were more likely to be older, to have heart failure and diabetes, and to have lower eGFR. Adjusting for demographics, kidney function, and comorbidity, every doubling of sST2 was not associated with progression to eGFR <15 ml/min per 1.73 m2 or ESRD (adjusted hazard ratio 1.02, 95% confidence interval = 0.76-1.38). Every doubling of galectin-3 was significantly associated with a 38% (adjusted hazard ratio = 1.35, 95% confidence interval = 1.01-1.80) increased risk of progression to eGFR <15 ml/min per 1.73 m2 or ESRD. CONCLUSION: Higher concentrations of the cardiac biomarker galectin-3 may be associated with progression of CKD, highlighting potential novel mechanisms that may contribute to the progression of kidney disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Alam ML, Katz R, Bellovich KA, et al. Soluble ST2 and Galectin-3 and Progression of CKD. Kidney Int Rep. 2018. PMID: 30596173. doi:10.1016/j.ekir.2018.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。